Cellectis (CLLS) Research & Development (2015 - 2026)
Cellectis (CLLS) posted quarterly Research & Development of -$27.2 million for Q1 2026, down 23.96% year-over-year from -$35.8 million in Q1 2025, and down 11.26% quarter-over-quarter from -$24.4 million in Q4 2025.
Cellectis (CLLS) Research & Development (2015 - 2026) Analysis & Trends
Cellectis' Research & Development history runs 12 years deep, the most recent figure standing at -$27.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 23.96% year-over-year to -$27.2 million; the TTM figure through Mar 2026 stood at -$98.8 million (down 208.63% YoY), while the FY2025 annual figure was -$93.5 million, down 203.29% from the prior year.
- Research & Development for Q1 2026 stood at -$27.2 million, down from -$24.4 million in the prior quarter.
- The five-year high for Research & Development was $160.2 million in Q4 2024, with the low at -$27.2 million in Q1 2026.
- The 5-year median for Research & Development is -$23.1 million (2025), against an average of -$2.4 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development surged 801.42% in 2023, then sank 115.25% in 2025.
- Cellectis' Research & Development stood at -$21.4 million in 2022, then soared by 801.42% to $150.3 million in 2023, then climbed by 6.57% to $160.2 million in 2024, then tumbled by 115.25% to -$24.4 million in 2025, then dropped by 11.26% to -$27.2 million in 2026.
- Business Quant data shows CLLS's Research & Development at -$27.2 million in Q1 2026, -$24.4 million in Q4 2025, and -$24.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -27.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.19 Mn |
| Dec 31, 2025 | -24.44 Mn |
| Sep 30, 2025 | -24.07 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -21.93 Mn |
| Dec 31, 2024 | 160.21 Mn |
| Sep 30, 2024 | -23.83 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | -22.32 Mn |
| Dec 31, 2023 | 150.34 Mn |
| Sep 30, 2023 | -19.08 Mn |
| Jun 30, 2023 | -22.20 Mn |
| Mar 31, 2023 | -21.42 Mn |
| Dec 31, 2022 | -21.43 Mn |
| Sep 30, 2022 | -23.84 Mn |
| Jun 30, 2022 | -25.63 Mn |
| Mar 31, 2022 | -26.60 Mn |
| Dec 31, 2021 | -29.54 Mn |
| Sep 30, 2021 | -34.32 Mn |
| Jun 30, 2021 | -31.15 Mn |